

CONTENTS

ACKNOWLEDGMENT	a
LIST OF TABLES	ii
LIST OF FIGURES	iii
INTRODUCTION	1
Epilepsy	1
Biochemical Aspects of Epilepsy	11
Drug Treatment of the Epilepsies	17
Teratogenicity of Antiepileptic Drugs	20
Valproic Acid	22
THE AIM OF THE WORK	28
MATERIAL AND METHODS	29
RESULTS	59
DISCUSSION	82
SUMMARY AND CONCLUSION	92
REFERENCES	97
THE ARABIC SUMMARY	122

LIST OF TABLES

TABLE (1) : INCLUSION CRITERIA	29
TABLE (2) : EXCLUSION CRITERIA	29
TABLE (3): TOTAL NUMBER OF PATIENTS WITH ADVERSE DRUG REACTIONS.....	62
TABLE (4): NUMBER OF ADVERSE EVENTS REPORTS.....	63
TABLE (5): LIVER FUNCTION TESTS	64
TABLE (6): SERUM PROLACTIN LEVEL NGM/ML	67
TABLE (7): EFFECT OF SODIUM VALPROATE (400 MG/KG/ORAL/DAY) FOR 21 DAY, ON THE AVERAGE CONCENTRATION ($M \pm SE$) OF GABA (UG/GM WET TISSUE) IN VALPROATE TREATED RATS COMPARED WITH NORMAL RATS.	68
TABLE (8): EFFECT OF SODIUM VALPROATE (400 MG/KG/ORAL/DAY) FOR 21 DAY, ON THE AVERAGE CONCENTRATION ($M \pm SE$) ON 5HT (UG/GM WET TISSUE) IN VALPROATE TREATED RATS COMPARED WITH NORMAL RATS	70
TABLE (9): EFFECT OF ORAL ADMINISTRATION OF SODIUM VALPROATE (400 MG/KG/DAY) TO PREGNANT RATS ON DAY 1 TO 20 OF GESTATION ON THE RESORPTION AND SURVIVAL RATES ($M \pm SE$.).....	73
TABLE (10): EFFECT OF ORAL ADMINISTRATION OF SODIUM VALPROATE (400 MG/KG/DAY) TO PREGNANT RATS ON MATERNAL BODY WEIGHT GAIN AND FETAL BODY WEIGHT ($M \pm SE$).....	75
TABLE (11) FETUSES ABNORMALITIES	77